Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials

Neurological Sciences

Volumn 37, Issue 1, 2016, Pages 57-65

  Zhang, Wei ^a   Chen, Xue yan ^b   Su, Su wen ^b   Jia, Qing zhong ^b   Ding, Tao ^c   Zhu, Zhong ning ^b   Zhang, Tong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c HEBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Alzheimer disease; Melatonin; Neurodegenerative diseases; Parkinson disease; REM sleep behavior disorder; Sleep

Indexed keywords

MELATONIN; HYPNOTIC SEDATIVE AGENT;

ALZHEIMER DISEASE; AROUSAL; ARTICLE; COCHRANE LIBRARY; DEGENERATIVE DISEASE; DRUG EFFICACY; HUMAN; INSOMNIA; MEDLINE; NIGHT SLEEP; PARASOMNIA; PARKINSON DISEASE; PITTSBURGH SLEEP QUALITY INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; SLEEP DISORDER; SLEEP QUALITY; SLEEP TIME; SYSTEMATIC REVIEW; COMPLICATION; META ANALYSIS; NEURODEGENERATIVE DISEASES; SLEEP WAKE DISORDERS;

HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; NEURODEGENERATIVE DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP WAKE DISORDERS;

EID: 84955725894     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-015-2357-0     Document Type: Article

References (36)

1. Chen Y, Li S, Su L et al (2015) Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J Neurol. doi:10.1007/s00415-014-7630-2
2. Reiter RJ (1998) Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56(3):359–384
3. Pandi-Perumal SR, BaHammam AS, Brown GM et al (2013) Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res 23(3):267–300
4. Dardente H (2012) Melatonin-dependent timing of seasonal reproduction by the pars tuberalis: pivotal roles for long daylengths and thyroid hormones. J Neuroendocrinol 24:249–266
5. Cardinali DP, Srinivasan V, Brzezinski A et al (2012) Melatonin and its analogs in insomnia and depression. J Pineal Res 52:365–375
6. Radogna F, Diederich M, Ghibelli L (2010) Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 80:1844–1852
7. Scheer FA, Van Montfrans GA, Van Someren EJ et al (2004) Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43:192–197
8. Guido ME, Garbarino-Pico E, Contin MA et al (2010) Inner retinal circadian clocks and non-visual photoreceptors: novel players in the circadian system. Prog Neurobiol 92:484–504
9. Dawson D, Armstrong SM (1996) Chronobiotics-drugs that shift rhythms. Pharmacol Ther 69:15–36
10. Galano A, Tan DX, Reiter RJ (2011) Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 51:1–16
11. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX et al (2010) Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 17:4462–4481
12. Reiter RJ, Tan DX, Qi W et al (2000) Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 9(3–4):160–171
13. Ferracioli-Oda E, Qawasmi A, Bloch MH (2013) Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 8(5):e63773
14. Raggi A, Ferri R (2010) Sleep disorders in neurodegenerative diseases. Eur J Neurol 17(11):1326–1338
15. Higgins JPT, Altman DG, Sterne JAC (Eds.) Chapter 8: assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. The Cochrane Collaboration 2011. http://www.cochrane-handbook.org
16. Paul M, Lador A, Grozinsky-Glasberg S et al. (2014) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1:CD003344
17. McCleery J, Cohen DA, Sharpley AL (2014) Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev 3:CD009178
18. Serfaty M, Kennell-Webb S, Warner J et al (2002) Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Intl J Geriatr Psych 17(12):1120–1127
19. Asayama K, Yamadera H, Ito T et al (2003) Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 70(4):334–341
20. Singer C, Tractenberg RE, Kaye J et al (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in alzheimer’s disease. Sleep 26(7):893–901
21. Dowling GA, Mastick J, Colling E et al (2005) Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 6(5):459–466
22. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA et al (2007) Effect of exogenous melatonin on sleep and motor dysfunction in parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neuro 254(4):459–64
23. Dowling GA, Burr RL, Van Someren EJ et al (2008) Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease. J Am Geriatr Soc 56(2):239–246
24. Gehrman PR, Connor DJ, Martin JL et al (2009) Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with alzheimer disease. Am J Psychiat 17(2):166–169
25. Wade AG, Farmer M, Harari G et al (2014) Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 9:947–961
26. Kunz D, Mahlberg R (2010) A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 19(4):591–596
27. Lin L, Huang QX, Yang SS et al (2013) Melatonin in Alzheimer’s disease. Int J Mol Sci 14(7):14575–14593
28. Rothman SM, Mattson MP (2012) Sleep disturbances in Alzheimer’s and Parkinson’s diseases. NeuroMol Med 14(3):194–204
29. Wu YH, Zhou JN, Van Heerikhuize J et al (2007) Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol Aging 28(8):1239–1247
30. Brusco LI, Fainstein I, Marquez M, Cardinali DP (1999) Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept 8(1–2):126–131
31. Villa C, Ferini-Strambi L, Combi R (2015) The synergistic relationship between Alzheimer’s disease and sleep disorders: an update. J Alzheimers Dis 46:571–580
32. Liguori C, Romigi A, Nuccetelli M et al (2014) Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 71(12):1498–1505
33. Polimeni G, Esposito E, Bevelacqua V et al (2014) Role of melatonin supplementation in neurodegenerative disorders. Front Biosci 19:429–446
34. McCarter SJ, Boswell CL, Louis EKS et al (2013) Treatment outcomes in REM sleep behavior disorder. Sleep Med 14(3):237–242
35. Howell MJ, Schenck CH (2015) Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol 72(6):707–712
36. Boot BP (2015) Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther doi:10.1186/s13195-015-0128-z